NAV

D-glucose

Enzymes (2)Carriers (1)Transporters (14)

Identification

Name
D-glucose
Accession Number
DB01914
Description

Glucose is a simple sugar (monosaccharide) generated during phosynthesis involving water, carbon and sunlight in plants. It is produced in humans via hepatic gluconeogenesis and breakdown of polymeric glucose forms (glycogenolysis). It circulates in human circulation as blood glucose and acts as an essential energy source for many organisms through aerobic or anaerobic respiration and fermentation.2 It is primarily stored as starch in plants and glycogen in animals to be used in various metabolic processes in the cellular level. Its aldohexose stereoisomer, dextrose or D-glucose, is the most commonly occurring isomer of glucose in nature. L-glucose is a synthesized enantiomer that is used as a low-calorie sweetener and laxative.10 The unspecified form of glucose is commonly supplied as an injection for nutritional supplementation or metabolic disorders where glucose levels are improperly regulated.12 Glucose is listed on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.

Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Structure
Thumb
3D
Similar Structures
Weight
Average: 180.1559
Monoisotopic: 180.063388116
Chemical Formula
C6H12O6
Synonyms
  • aldehydo-D-glucose
  • Anhydrous dextrose
  • D-Glucose in linear form
  • D-glucose, anhydrous
  • D(+)-Glucose
  • Dextrose anhydrous
  • Dextrose, anhydrous
  • Glucose anhydrous
  • Glucose, anhydrous
External IDs
  • NSC-406891

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

Glucose pharmaceutical formulations (oral tablets, injections) are indicated for caloric supply and carbohydrate supplementation in case of nutrient deprivation. It is also used for metabolic disorders such as hypoglycemia.13

Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Blood glucose is an obligatory energy source for humans involved in various cellular activities, and it also acts as a signaling molecule for diverse glucose-sensing molecules and proteins. Glucose undergoes oxidation into carbon dioxide, water, and yields energy molecules in the process of glycolysis and subsequent citric cycle and oxidative phosphorylation.6 Glucose is readily converted into fat in the body which can be used as a source of energy as required. Under a similar conversion into storage of energy, glucose is stored in the liver and muscles as glycogen.11 Glucose stores are mobilized in a regulated manner, depending on the tissues' metabolic demands. Oral glucose tablets or injections serve to increase the supply of glucose and oral glucose administration is more effective in stimulating insulin secretion because it stimulates the incretin hormones from the gut, which promotes insulin secretion.10

Mechanism of action

Glucose supplies most of the energy to all tissues by generating energy molecules ATP and NADH during a series of metabolism reactions called glycolysis. Glycolysis can be divided into two main phases where the preparatory phase is initiated by the phosphorylation of glucose by hexokinase to form glucose 6-phosphate.5 The addition of the high-energy phosphate group activates glucose for the subsequent breakdown in later steps of glycolysis and is the rate-limiting step. Products end up as substrates for following reactions, to ultimately convert C6 glucose molecule into two C3 sugar molecules. These products enter the energy-releasing phase where the total of 4ATP and 2NADH molecules are generated per one glucose molecule. The total aerobic metabolism of glucose can produce up to 36 ATP molecules. These energy-producing reactions of glucose are limited to D-glucose as L-glucose cannot be phosphorylated by hexokinase.11 Glucose can act as precursors to generate other biomolecules such as vitamin C. It plays a role as a signaling molecule to control glucose and energy homeostasis. Glucose can regulate gene transcription, enzyme activity, hormone secretion, and the activity of glucoregulatory neurons. The types, number, and kinetics of glucose transporters expressed depends on the tissues and fine-tunes glucose uptake, metabolism, and signal generation to preserve cellular and whole body metabolic integrity.4

Absorption

Polysaccharides can be broken down into smaller units by pancreatic and intestinal glycosidases or intestinal flora. Sodium-dependent glucose transporter SGLT1 and GLUT2 (SLC2A2) play predominant roles in intestinal transport of glucose into the circulation.1 SGLT1 is located in the apical membrane of the intestinal wall while GLUT2 is located in the basolateral membrane, but it was proposed that GLUT2 can be recruited into the apical membrane after a high luminal glucose bolus allowing bulk absorption of glucose by facilitated diffusion.3 Oral preparation of glucose reaches the peak concentration within 40 minutes and the intravenous infusions display 100% bioavailability.6

Volume of distribution

The mean volume of distribution after intravenous infusion is 10.6L.7

Protein binding
Not Available
Metabolism

Glucose can undergo aerobic oxidation in conjunction with the synthesis of energy molecules. Glycolysis is the initial stage of glucose metabolism where one glucose molecule is degraded into two molecules of pyruvate via substrate-level phosphorylation. These products are transported to the mitochondria where they are further oxidized into oxygen and carbon dioxide.5

Hover over products below to view reaction partners

Route of elimination

Glucose can be renally excreted.8

Half-life

The approximate half-life is 14.3 minutes following intravenous infusion. Gut glucose half-life was markedly higher in females (79 ± 2 min) than in males (65 ± 3 min, P < 0.0001) and negatively related to body height (r = -0.481; P < 0.0001).7

Clearance

The mean metabolic clearance rate of glucose (MCR) for the 10 subjects studied at the higher insulin level was 2.27 ± 0.37 ml/kg/min at euglycemia and fell to 1.51±0.21 ml/kg/ at hyperglycemia. The mean MCR for the six subjects studied at the lower insulin level was 1.91 ± 0.31 ml/kg/min at euglycemia.8

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Oral LD50 value in rats is 25800mg/kg. The administration of glucose infusions can cause fluid and solute overloading resulting in dilution of the serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. Hypersensitivity reactions may also occur including anaphylactic/anaphylactoid reactions from oral tablets and intravenous infusions.12

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
D-glucose monohydrateLX22YL083G77938-63-7SPFMQWBKVUQXJV-BTVCFUMJSA-N
Active Moieties
NameKindUNIICASInChI Key
Dextrose, unspecified formunknownIY9XDZ35W2Not AvailableNot applicable
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
25% Dextrose InfantInjection, solution250 mg/1mLIntravenousHf Acquisition Co. Llc, Dba Health First2018-08-19Not applicableUS flag
5% DextroseInjection, solution5000 mg/100mLIntravenousSc Infomed Fluids Srl2017-04-242017-06-15US flag
5% DextroseInjection, solution5 g/100mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2019-10-14Not applicableUS flag
5% DextroseInjection, solution5 g/100mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2018-10-18Not applicableUS flag
50% DextroseInjection, solution25 g/50mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2018-09-19Not applicableUS flag
DextroseInjection, solution25 mg/1mLIntravenousCantrell Drug Company2011-02-182015-01-14US flag
DextroseInjection, solution25 g/50mLIntravenousGeneral Injectables & Vaccines, Inc2010-07-01Not applicableUS flag
DextroseInjection, solution10 g/100mLIntravenousHospira, Inc.2005-01-312021-08-01US flag
DextroseInjection, solution25 g/50mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2018-09-13Not applicableUS flag
DextroseInjection, solution20 g/100mLIntravenousHospira, Inc.2005-09-122020-12-01US flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
DextroseInjection, solution50 mg/1mLIntravenousBecton Dickinson and Company2016-10-21Not applicableUS flag
DextroseInjection, solution100 mg/1mLIntravenousFresenius Kabi USA, LLC2019-03-29Not applicableUS flag
DextroseInjection, solution100 mg/1mLIntravenousBecton Dickinson and Company2020-02-05Not applicableUS flag
DextroseInjection, solution50 mg/1mLIntravenousFresenius Kabi USA, LLC2016-10-21Not applicableUS flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AGF Mesenchymal Capillary 5 pcsLiquid0.06 mg/6mLTopicalLCELLS SA DE CV2019-12-31Not applicableUS flag
AGF Mesenchymal Capillary IndividualLiquid0.06 mg/6mLTopicalLCELLS SA DE CV2019-12-31Not applicableUS flag
LingteaPowder, for solution5 g/100gOralLinger Water2018-06-25Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Acd AD-glucose monohydrate (2.45 g/100mL) + Citric acid monohydrate (0.8 g/100mL) + Sodium citrate dihydrate (2.2 g/100mL)Injection, solutionIntravenousTerumo Bct, Ltd.2002-02-25Not applicableUS flag
Acd AD-glucose monohydrate (2.45 g/100mL) + Citric acid monohydrate (0.80 g/100mL) + Sodium citrate (2.2 g/100mL)Injection, solutionIntravenousTerumo BCT Ltd2002-02-25Not applicableUS flag
Acd AD-glucose monohydrate (2.45 g/100mL) + Citric acid monohydrate (0.8 g/100mL) + Sodium citrate dihydrate (2.2 g/100mL)Injection, solutionIntravenousTerumo Bct, Ltd.2002-02-25Not applicableUS flag
ACD Blood-Pack Units (PL 146 Plastic)D-glucose monohydrate (1.65 g/67.5mL) + Citric acid (493 mg/67.5mL) + Sodium citrate dihydrate (1.48 g/67.5mL)SolutionExtracorporealFenwal, Inc.2007-03-01Not applicableUS flag
Acd-AD-glucose monohydrate (2.45 g/100mL) + Citric acid monohydrate (0.73 g/100mL) + Sodium citrate (2.20 g/100mL)SolutionExtracorporealHaemonetics Corporation1987-11-06Not applicableUS flag
Acd-AD-glucose monohydrate (2.45 g/100mL) + Citric acid (730 mg/100mL) + Sodium citrate (2.2 g/100mL)SolutionExtracorporealFenwal, Inc.2012-10-24Not applicableUS flag
Acd-AD-glucose monohydrate (12.25 g/500mL) + Citric acid (3.65 g/500mL) + Sodium citrate (11 g/500mL)SolutionExtracorporealFenwal, Inc.2007-03-01Not applicableUS flag
Additive Formula 3D-glucose monohydrate (1.1 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) + Sodium phosphate, monobasic, monohydrate (0.28 g/100mL)SolutionIntravenousTerumo Bct, Ltd2002-05-29Not applicableUS flag
Additive Formula 3D-glucose monohydrate (1.1 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) + Sodium phosphate, monobasic, monohydrate (0.28 g/100mL)SolutionIntravenousTerumo Bct, Ltd2002-05-29Not applicableUS flag
Additive Formula 3D-glucose monohydrate (1.1 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL) + Sodium phosphate, monobasic, monohydrate (0.28 g/100mL)SolutionIntravenousTerumo Bct, Ltd2002-05-29Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
5% DextroseD-glucose monohydrate (5000 mg/100mL)Injection, solutionIntravenousSc Infomed Fluids Srl2017-04-242017-06-15US flag
AGF Mesenchymal Capillary 5 pcsD-glucose (0.06 mg/6mL)LiquidTopicalLCELLS SA DE CV2019-12-31Not applicableUS flag
AGF Mesenchymal Capillary IndividualD-glucose (0.06 mg/6mL)LiquidTopicalLCELLS SA DE CV2019-12-31Not applicableUS flag
Anti NauseaD-glucose monohydrate (1.87 g/5mL) + Fructose (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralMedicine Shoppe International2008-02-062013-06-09US flag
ClinimixD-glucose monohydrate (100.00 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + L-Lysine (2.00 g/1L) + Leucine (2.01 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L)SolutionIntravenousBaxter Healthcare Corporation2017-10-252019-11-30US flag
ClinimixD-glucose monohydrate (300.00 g/2L) + Alanine (17.60 g/2L) + Arginine (9.78 g/2L) + Calcium chloride dihydrate (0.66 g/2L) + Dipotassium phosphate (5.22 g/2L) + Glycine (8.76 g/2L) + Histidine (4.08 g/2L) + Isoleucine (5.10 g/2L) + L-Lysine (4.93 g/2L) + Leucine (6.20 g/2L) + Magnesium chloride hexahydrate (1.02 g/2L) + Methionine (3.40 g/2L) + Phenylalanine (4.76 g/2L) + Proline (5.78 g/2L) + Serine (4.25 g/2L) + Sodium acetate trihydrate (5.94 g/2L) + Sodium chloride (1.54 g/2L) + Threonine (3.57 g/2L) + Tryptophan (1.53 g/2L) + Tyrosine (0.34 g/2L) + Valine (4.93 g/2L)SolutionIntravenousBaxter Healthcare Corporation2017-10-252019-11-30US flag
ClinimixD-glucose monohydrate (75.00 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + L-Lysine (2.00 g/1L) + Leucine (2.01 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L)SolutionIntravenousBaxter Healthcare Corporation2017-10-252019-11-30US flag
DextroseD-glucose monohydrate (25 g/50mL)Injection, solutionIntravenousMc Kesson2010-05-032017-08-02US flag
DextroseD-glucose monohydrate (2.5 g/50mL)InjectionIntravenousBaxter Healthcare Corporation2017-10-132017-10-13US flag
DextroseD-glucose monohydrate (50 mg/100mL)InjectionIntravenousBaxter Healthcare Corporation2017-10-132017-10-13US flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Hexoses
Alternative Parents
Medium-chain aldehydes / Beta-hydroxy aldehydes / Alpha-hydroxyaldehydes / Secondary alcohols / Polyols / Primary alcohols / Organic oxides / Hydrocarbon derivatives
Substituents
Alcohol / Aldehyde / Aliphatic acyclic compound / Alpha-hydroxyaldehyde / Beta-hydroxy aldehyde / Carbonyl group / Hexose monosaccharide / Hydrocarbon derivative / Medium-chain aldehyde / Organic oxide
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
aldehydo-glucose, D-glucose (CHEBI:42758)

Chemical Identifiers

UNII
5SL0G7R0OK
CAS number
50-99-7
InChI Key
GZCGUPFRVQAUEE-SLPGGIOYSA-N
InChI
InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h1,3-6,8-12H,2H2/t3-,4+,5+,6+/m0/s1
IUPAC Name
(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal
SMILES
[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O

References

General References
  1. Thorens B, Mueckler M: Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E141-5. doi: 10.1152/ajpendo.00712.2009. Epub 2009 Dec 15. [PubMed:20009031]
  2. Ferraris RP: Dietary and developmental regulation of intestinal sugar transport. Biochem J. 2001 Dec 1;360(Pt 2):265-76. [PubMed:11716754]
  3. Roder PV, Geillinger KE, Zietek TS, Thorens B, Koepsell H, Daniel H: The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One. 2014 Feb 26;9(2):e89977. doi: 10.1371/journal.pone.0089977. eCollection 2014. [PubMed:24587162]
  4. Deng D, Sun P, Yan C, Ke M, Jiang X, Xiong L, Ren W, Hirata K, Yamamoto M, Fan S, Yan N: Molecular basis of ligand recognition and transport by glucose transporters. Nature. 2015 Oct 15;526(7573):391-6. doi: 10.1038/nature14655. Epub 2015 Jul 15. [PubMed:26176916]
  5. Jiang G, Zhang BB: Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E671-8. [PubMed:12626323]
  6. Anderwald C, Gastaldelli A, Tura A, Krebs M, Promintzer-Schifferl M, Kautzky-Willer A, Stadler M, DeFronzo RA, Pacini G, Bischof MG: Mechanism and effects of glucose absorption during an oral glucose tolerance test among females and males. J Clin Endocrinol Metab. 2011 Feb;96(2):515-24. doi: 10.1210/jc.2010-1398. Epub 2010 Dec 8. [PubMed:21147888]
  7. Kouider S, Kolb FE, Lippmann R: [Behavior of various blood constituents (glucose, fructose, insulin, lactate, pyruvate, free fatty acids, inorganic phosphate) and the half-life of monosaccharides in plasma after i.v infusion of glucose, fructose, galactose and invert sugar solutions in ruminants. 3. Studies in sheep]. Arch Exp Veterinarmed. 1978;32(5):715-25. [PubMed:736717]
  8. JOKIPII SG, TURPEINEN O: Kinetics of elimination of glucose from the blood during and after a continuous intravenous injection. J Clin Invest. 1954 Mar;33(3):452-8. [PubMed:13143092]
  9. Revers RR, Kolterman OG, Olefsky JM: Relationship between serum glucose level and the metabolic clearance rate of glucose in non-insulin-dependent diabetes mellitus. Diabetes. 1983 Jul;32(7):627-32. [PubMed:6345242]
  10. Rang, H. P. and Dale, M. M. (2012). Rang and Dale's Pharmacology (7th ed.). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
  11. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, and Darnell J. (2000). Molecular Cell Biology (4th ed.). New York: W. H. Freeman. [ISBN:0-7167-3136-3]
  12. Baxter Health GLUCOSE INTRAVENOUS INFUSION BP Product information [Link]
  13. Glucose injection (Viaflex bag) Product information [Link]
PubChem Compound
107526
PubChem Substance
46507147
ChemSpider
96749
RxNav
349730
ChEBI
42758
ZINC
ZINC000100009383
PDBe Ligand
GLO
Wikipedia
Glucose
PDB Entries
1ac0 / 1ez9 / 1fbo / 1fqc / 1fqd / 1xyb / 1xym / 2zyd / 3fxp / 3kbn …
show 7 more
FDA label
Download (142 KB)
MSDS
Download (47 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedBasic ScienceType 2 Diabetes Mellitus1
4CompletedOtherAnaesthesia therapy / Anorectal Disorders / Drug Effect / General Surgery / Outpatients1
4CompletedTreatmentChronic Renal Failure (CRF)1
4CompletedTreatmentContrast Induced Nephropathy (CIN) / Prophylaxis of Contrast-induced nephropathy1
4CompletedTreatmentDehydration / Hypernatremia / Hypokalemia / Hyponatremia1
4CompletedTreatmentHeart Failure1
4Not Yet RecruitingTreatmentFlu caused by Influenza1
4RecruitingTreatmentLateral Epicondylitis1
4WithdrawnSupportive CareMalnutrition1
3CompletedTreatmentBronchiolitis / Gastroenteritis / Sepsis / Urinary Tract Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionIntravenous10 %
SolutionIntravenous20 %
SolutionIntravenous30 %
SolutionIntravenous5 %
SolutionIntravenous50 %
SolutionIntravenous3.3 g/100mL
SolutionIntravenous3.75 g/100mL
SolutionIntravenous3.2 g/100mL
Solution
Injection20 %
Injection, solutionIntravenous250 mg/1mL
Injection, solutionIntravenous5000 mg/100mL
Solution5 %
Injection5 %
Injection10 %
SolutionHemodialysis7.52 g/L
SolutionHemodialysis0.257 g/1000ml
SolutionExtracorporeal
LiquidTopical0.06 mg/6mL
SolutionIntravenous0.25 g/mL
Injection, solutionIntravenous2.5 g/500mL
SolutionIntravenous2.55 g/L
SolutionIntravenous1.79 g/L
LiquidOral
Injection, solutionExtracorporeal
SolutionExtracorporeal0.8 g/100ml
SolutionOral289.2 mg
SolutionIntravenous4.3 %
SolutionIntravenous drip4 % w/v
SolutionIntravenous3.3 %
Injection, solutionIntravenous0.45 %
InjectionIntravenous10 %
InjectionIntravenous20 %
InjectionIntravenous30 %
InjectionIntravenous40 %
InjectionIntravenous50 %
SolutionIntraperitoneal0.1838 g/L
SolutionIntraperitoneal0.2573 g/L
SolutionIntraperitoneal1.5 g/100ml
SolutionIntraperitoneal2.5 g/100ml
SolutionIntraperitoneal4.25 g/100ml
Injection, solutionIntraperitoneal538 mg/100mL
SolutionIntraperitoneal16.5 g/L
SolutionIntraperitoneal5.786 g/L
SolutionIntravenous5 g/100ml
SolutionIntravenous10 g/100ml
SolutionIntravenous50 g/L
SolutionIntravenous3 g/L
SolutionIntravenous200 mg/100ml
SolutionIntravenous80 mg/100ml
Powder, for solutionOral289.2 mg
SolutionIntraspinal20 mg
SolutionParenteral20 mg
Injection, solutionIntraperitoneal0.1838 g/L
Injection, solutionIntraperitoneal5.786 g/L
Solution0.1838 g/L
SolutionIntraperitoneal46.75 g/L
SolutionHemodialysis0.1838 g/L
Solution0.2573 g/L
SolutionIntraperitoneal0.0003 g
Injection, solutionIntravenous5.786 g/L
Powder, for solutionOral99 g
SolutionIntravenous0.1491 g
SolutionIntravenous0.27 g/L
Solution, concentrateHemodialysis99 g
InjectionIntravenous25 G/500ML
InjectionIntravenous5 %
SolutionIntraperitoneal
Injection50 % W/V
SolutionIntravenous100 mg
SolutionIntravenous150 g
InjectionParenteral33 g
SolutionParenteral0.9 g
SolutionIntravenous5 g
SolutionIntravenous0.33 g
SolutionParenteral0.05 g
SolutionIntravenous0.9 g
SolutionIntravenous0.45 g
SolutionIntravenous9 mg
SolutionIntravenous50 g
InjectionIntravenous2.50 g/50mL
InjectionIntravenous50 mg/50mL
InjectionIntravenous50 mg/100mL
Injection, solutionIntravenous10 g/100mL
Injection, solutionIntravenous100 mg/1mL
Injection, solutionIntravenous100 g/1000mL
Injection, solutionIntravenous20 g/100mL
Injection, solutionIntravenous20.00 g/100.00mL
Injection, solutionIntravenous25 mg/1mL
Injection, solutionIntravenous25 g/50mL
Injection, solutionIntravenous30 g/100mL
Injection, solutionIntravenous30.00 g/100.00mL
Injection, solutionIntravenous40 g/100mL
Injection, solutionIntravenous40.00 g/100.00mL
Injection, solutionIntravenous5 g/100mL
Injection, solutionIntravenous50 g/1000mL
Injection, solutionIntravenous50 mg/1mL
Injection, solutionIntravenous50 g/100mL
Injection, solutionIntravenous50.00 g/100.00mL
Injection, solutionIntravenous60.00 g/100.00mL
Injection, solutionIntravenous70 g/100mL
Injection, solution, concentrateIntravenous10 g/100mL
InjectionIntravenous10 G/100ml
InjectionIntravenous27.71 g
InjectionIntravenous55 g
InjectionParenteral250 mg/1mL
InjectionParenteral500 mg/1mL
SolutionIntraperitoneal5.08 mg/100ml
SolutionIntraperitoneal; Irrigation0.1837 mg
SolutionIntraperitoneal18.3 mg
Injection, solutionIntraperitoneal
SolutionParenteral
SolutionIntraperitoneal1.36 %
SolutionIntraperitoneal2.27 %
SolutionIntraperitoneal3.86 %
Solution22.7 g/L
Solution13.6 g/L
SolutionIntraperitoneal22.7 g/L
Solution38.6 g/L
SolutionIntraperitoneal13.6 g/L
SolutionIntraperitoneal38.6 g/L
SolutionIntravenous50 mg
Injection, solutionIntravenous4.9 g/1000ml
Injection, solutionIntravenous7.35 g/1500ml
Injection, solutionIntravenous9.8 g/2000ml
SolutionIntravenous4.21 g/1000ml
SolutionHemodialysis1.98 g/1000ml
SolutionHemodialysis0.91 g/1000ml
SolutionIntravenous1.098 g/L
SolutionHemodialysis10.39 g/L
Injection, solutionIntravenous10.39 g/L
InjectionIntravenous5.5 G/100ML
Granule, for solutionOral1.5 g
Injection, solutionIntravenous2.34 g/L
Injection, solutionIntravenous0.91 g/L
Injection, solutionIntravenous5.26 g/L
Injection, solutionIntravenous3.2 g/L
Injection, solutionIntravenous3.38 g
InjectionIntrathecal
SolutionIntravenous0.298 mg/ml
Granule, for solutionOral650 mg
Powder, for solutionOral2.9 g
SolutionOral0.294 g
Injection, emulsionIntravenous11.41 g/1085ml
Injection, emulsionIntravenous11.41 g/1435ml
Injection, emulsionIntravenous13.17 g/2020ml
Injection, emulsionIntravenous7.08 g/1085ml
Injection, emulsionIntravenous9.46 g/1450ml
EmulsionParenteral3.99 g/1085ml
EmulsionParenteral2.05 g/1085ml
Injection200 mg/ml
Solution, concentrateHemodialysis0.864 mg
PowderOral13.5 g
Powder, for solutionOral24.75625 g
SolutionOral50 g
Tablet, chewableOral4 g
SolutionOral75 G/180ML
SolutionIntravenous10 g
InjectionIntravenous2.5 g/50mL
InjectionIntravenous5 g/100mL
Injection, solutionOphthalmic35 %
Injection, solutionParenteral20 %
Injection, solutionParenteral70 %
Injection, solutionParenteral5 %
Injection, solutionParenteral30 %
Injection, solutionParenteral50 %
InjectionParenteral2.5 %
Injection, solutionParenteral2.5 %
Injection, solutionParenteral4.27 %
Injection, solutionIntravenous25 g/L
Injection, solutionIntravenous47 g/L
Injection, solutionIntravenous42.7 g/L
Injection, solutionIntravenous110 g/L
Injection, solutionIntravenous55 g/L
Injection, solutionIntravenous100 g/L
Injection, solutionIntravenous50 g/L
Injection, solutionParenteral10 %
Injection, solutionParenteral33 %
SyrupOral500 MG/ML
SyrupOral75 MG/150ML
SolutionOral25 g
Powder, for solutionOral24.8 g
SolutionHemodialysis2.4 g/1000ml
LiquidHemodialysis9.74 g/L
SolutionHemodialysis
SolutionOral216 mg
SolutionOral30 mg
SolutionOral29.1 mg
SolutionOral0.2892 g
SolutionOral0.29 g
SolutionOral0.275 g
SolutionOral275 mg
InjectionIntravenous
InjectionIntravenous50 G/500ML
InjectionIntravenous10 %w/v
Injection, solutionIntravenous30 % w/v
Injection, solutionIntravenous40 % w/v
InjectionIntravenous5 %w/v
Injection, solutionIntravenous50 % w/v
InjectionIntravenous4.25 %w/v
Injection, solutionIntravenous10 % w/v
Injection, solutionIntravenous4 % w/v
InjectionParenteral5 g
SolutionIntravenous160 mg
InjectionParenteral150 mg
SolutionParenteral30 g
SolutionParenteral150 mg
InjectionParenteral300 mg
InjectionIntravenous3.33 %
Injection, solutionIntravenous50 g
SolutionIntravenous2.5 %
SolutionIntravenous3.33 %
SolutionIntravenous3.75 %
TabletVaginal
Injection, emulsionIntravenous
Injection, emulsionIntravenous467 mg/100mL
InjectionIntravenous110 g
InjectionIntravenous165 g
InjectionIntravenous220 g
InjectionIntravenous275 g
InjectionIntravenous107 g
InjectionIntravenous143 g
InjectionIntravenous178 g
SolutionIntravenous20.475 %
Injection, emulsionIntravenous10.5 g
Injection, emulsionIntravenous14 g
Injection, emulsionIntravenous2.1 g
Injection, emulsionIntravenous3.1 g
Injection, emulsionIntravenous4.2 g
Injection, emulsionIntravenous7 g
SolutionIntravenous50 mg/mL
Injection, solutionIntraspinal
Powder, for solutionOral5 g/100g
PowderOral3.5 g
InjectionIntravenous
KitIntravenous
SolutionHemodialysis0.2205 g/1000ml
SolutionHemodialysis2.94 g/1000ml
SolutionHemodialysis; Intravenous0.1017 g/L
SolutionHemodialysis0.2205 g/L
Powder, for solutionOral658 mg
SyrupOral
Injection, solutionIntravenous200 mg/100ml
SolutionIntravenous50 g/100ml
InjectionIntravenous3.33 g/100ml
Injection, solutionIntravenous33.3 g/L
SolutionIntravenous55 g/L
SolutionIntravenous5.5 g/100ml
SolutionIntravenous8.518 g
Powder, for solutionOral0.875 g
Injection, emulsionParenteral2.33 g
Injection, emulsionIntravenous1.03 g
Injection, emulsionIntravenous1.83 g
EmulsionIntravenous1.83 g
InjectionIntravenous1.03 g
EmulsionIntravenous20 mg
EmulsionIntravenous16 g
Injection, emulsionIntravenous3.88 g/1000ml
EmulsionParenteral20 g/l
EmulsionParenteral3.88 g
EmulsionIntravenous88 g
Injection, emulsionIntravenous120 g
Injection, emulsionIntravenous160 g
Injection, emulsionIntravenous4.66 g/1000ml
EmulsionParenteral1.872 g/l
Injection, emulsionIntravenous150 g
Injection, emulsionIntravenous225 g
Injection, emulsionIntravenous300 g
Injection, emulsionIntravenous4.25 g/625ml
EmulsionParenteral6.792 g/l
EmulsionIntravenous6.792 mg
EmulsionIntravenous150 g
EmulsionIntravenous225 g
EmulsionParenteral2.4 g/l
EmulsionParenteral2.88 g/l
Injection, emulsionIntravenous5.82 g/1250ml
EmulsionIntravenous4.656 g
EmulsionParenteral6.792 g
EmulsionIntravenous6.792 g
Injection, solution0.6 g/L
Injection, emulsionIntravenous12 g/1500ml
Injection, emulsionIntravenous32 g/1000ml
Injection, emulsionIntravenous0.52 g/1000ml
Injection, emulsionIntravenous0.42 g/1000ml
InjectionIntravenous2.27 g/l
InjectionIntravenous4.12 g/l
EmulsionIntravenous4 g
SolutionIntravenous7.14 g
SolutionIntravenous9.52 g
SolutionIntravenous11.9 g
EmulsionIntravenous6.41 g
EmulsionIntravenous9.61 g
EmulsionIntravenous12.82 g
Injection, emulsionIntravenous6.41 g/1000ml
SolutionIntravenous8.24 g
SolutionIntravenous12.36 g
SolutionIntravenous16.48 g
Injection, emulsionIntravenous8.24 g/1000ml
Injection, emulsionIntravenous180 g/1250ml
Injection, emulsionIntravenous270 g/1875ml
Injection, emulsionIntravenous90 g/625ml
Powder, for solutionOral3.24 g
Injection40 %
SolutionOral108.2 mg
SolutionOral294 mg
SolutionOral290 mg
SolutionOral29.4 mg
SolutionOral295 mg
EmulsionIntravenous3 g
Injection, emulsionIntravenous3.66 g
Injection, emulsionIntravenous5.5 g
Injection, emulsionIntravenous7.33 g
Injection, emulsionIntravenous9.16 g
Injection, emulsionIntravenous3.66 g/1000ml
Injection, solutionIntraperitoneal18.3 mg/100mL
SolutionIntraperitoneal15 g/L
SolutionIntraperitoneal25 g/L
SolutionIntravenous25 g/L
SolutionIntraperitoneal42.5 g/L
Injection, solutionIntravenous
Injection, solutionIntravenous5 %
SolutionIntravenous1.6 g/100mL
KitHemodialysis
SolutionHemodialysis; Intravenous
SolutionIntravenous2.033 g/L
SolutionHemodialysis0.257 g/L
Powder, for solutionOral25 g
SolutionUnknown
Powder, for solutionOral14.1463 g
Injection, emulsionIntravenous4.4 g/1000ml
EmulsionParenteral3.1 g
Injection, emulsionIntravenous7.1 g/1000ml
EmulsionParenteral50 g
Solution0.184 g/L
Injection, solutionIntraperitoneal0.184 g/L
SolutionIntravenous0.41 g
SolutionParenteral25.7 mg
SolutionIntraperitoneal25.7 mg
SolutionIntravenous0.1 g
SolutionIntravenous0.05 g
SolutionIrrigation; Parenteral55 g
Solution192.5 g/100ml
Injection, solutionIntraperitoneal5.38 g/l
Injection, solutionIntraperitoneal5.67 g/l
SolutionIntraperitoneal22.73 g/L
SolutionIntravenous
Injection, solutionIntravenous80 mg/100mL
EmulsionParenteral18.75 g
EmulsionParenteral
InjectionIntravenous1000 mg
Injection, solutionIntravenous3 g
Injection, solutionIntravenous0.2 %
Injection, solutionIntravenous0.4 %
Granule, for solutionOral6.25 mg
Powder, for solutionOral375 mg
InjectionIntravenous25 g
EmulsionParenteral7 g
EmulsionParenteral28 g/1000ml
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)146 MSDS
water solubilitySolubleMSDS
Predicted Properties
PropertyValueSource
Water Solubility261.0 mg/mLALOGPS
logP-2.4ALOGPS
logP-3.6ChemAxon
logS0.16ALOGPS
pKa (Strongest Acidic)11.8ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area118.22 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity37.35 m3·mol-1ChemAxon
Polarizability16.23 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.8269
Blood Brain Barrier+0.5569
Caco-2 permeable-0.8842
P-glycoprotein substrateNon-substrate0.6771
P-glycoprotein inhibitor INon-inhibitor0.9568
P-glycoprotein inhibitor IINon-inhibitor0.9378
Renal organic cation transporterNon-inhibitor0.9388
CYP450 2C9 substrateNon-substrate0.8595
CYP450 2D6 substrateNon-substrate0.8847
CYP450 3A4 substrateNon-substrate0.7206
CYP450 1A2 substrateNon-inhibitor0.8505
CYP450 2C9 inhibitorNon-inhibitor0.9411
CYP450 2D6 inhibitorNon-inhibitor0.9366
CYP450 2C19 inhibitorNon-inhibitor0.942
CYP450 3A4 inhibitorNon-inhibitor0.9065
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9652
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8077
BiodegradationReady biodegradable0.9596
Rat acute toxicity1.0110 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9883
hERG inhibition (predictor II)Non-inhibitor0.9385
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Enzymes

Details1. Hexokinase-1
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Mannokinase activity
Specific Function
Not Available
Gene Name
HK1
Uniprot ID
P19367
Uniprot Name
Hexokinase-1
Molecular Weight
102485.1 Da
References
  1. Rose IA, O'Connell EL, Litwin S: Determination of the rate of hexokinase-glucose dissociation by the isotope-trapping method. J Biol Chem. 1974 Aug 25;249(16):5163-8. [PubMed:4604308]
Details2. Glucokinase
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Glucose binding
Specific Function
Catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. Glucokinase has a high Km for glucose, and so it is effective only when gluco...
Gene Name
GCK
Uniprot ID
P35557
Uniprot Name
Glucokinase
Molecular Weight
52191.07 Da
References
  1. Matschinsky FM: Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes. 1990 Jun;39(6):647-52. [PubMed:2189759]

Carriers

Details1. Serum albumin
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Ranganarayanan P, Thanigesan N, Ananth V, Jayaraman VK, Ramakrishnan V: Identification of Glucose-Binding Pockets in Human Serum Albumin Using Support Vector Machine and Molecular Dynamics Simulations. IEEE/ACM Trans Comput Biol Bioinform. 2016 Jan-Feb;13(1):148-57. doi: 10.1109/TCBB.2015.2415806. [PubMed:26886739]

Transporters

Details1. Solute carrier family 2, facilitated glucose transporter member 1
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Xenobiotic transporter activity
Specific Function
Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including b...
Gene Name
SLC2A1
Uniprot ID
P11166
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 1
Molecular Weight
54083.325 Da
References
  1. Mueckler M, Thorens B: The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38. doi: 10.1016/j.mam.2012.07.001. [PubMed:23506862]
Details2. Solute carrier family 2, facilitated glucose transporter member 2
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Hexose transmembrane transporter activity
Specific Function
Facilitative glucose transporter. This isoform likely mediates the bidirectional transfer of glucose across the plasma membrane of hepatocytes and is responsible for uptake of glucose by the beta c...
Gene Name
SLC2A2
Uniprot ID
P11168
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 2
Molecular Weight
57488.955 Da
References
  1. Mueckler M, Thorens B: The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38. doi: 10.1016/j.mam.2012.07.001. [PubMed:23506862]
Details3. Solute carrier family 2, facilitated glucose transporter member 3
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Glucose transmembrane transporter activity
Specific Function
Facilitative glucose transporter that can also mediate the uptake of various other monosaccharides across the cell membrane (PubMed:9477959, PubMed:26176916). Mediates the uptake of glucose, 2-deox...
Gene Name
SLC2A3
Uniprot ID
P11169
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 3
Molecular Weight
53923.785 Da
References
  1. Mueckler M, Thorens B: The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38. doi: 10.1016/j.mam.2012.07.001. [PubMed:23506862]
Details4. Solute carrier family 2, facilitated glucose transporter member 4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Glucose transmembrane transporter activity
Specific Function
Insulin-regulated facilitative glucose transporter.
Gene Name
SLC2A4
Uniprot ID
P14672
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 4
Molecular Weight
54786.79 Da
References
  1. Mueckler M, Thorens B: The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38. doi: 10.1016/j.mam.2012.07.001. [PubMed:23506862]
Details5. Solute carrier family 2, facilitated glucose transporter member 5
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Glucose transmembrane transporter activity
Specific Function
Cytochalasin B-sensitive carrier. Seems to function primarily as a fructose transporter.
Gene Name
SLC2A5
Uniprot ID
P22732
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 5
Molecular Weight
54973.42 Da
References
  1. Mueckler M, Thorens B: The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38. doi: 10.1016/j.mam.2012.07.001. [PubMed:23506862]
Details6. Solute carrier family 2, facilitated glucose transporter member 6
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Glucose transmembrane transporter activity
Specific Function
Facilitative glucose transporter; binds cytochalasin B with low affinity.
Gene Name
SLC2A6
Uniprot ID
Q9UGQ3
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 6
Molecular Weight
54538.55 Da
References
  1. Mueckler M, Thorens B: The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38. doi: 10.1016/j.mam.2012.07.001. [PubMed:23506862]
Details7. Solute carrier family 2, facilitated glucose transporter member 7
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Substrate-specific transmembrane transporter activity
Specific Function
High-affinity transporter for glucose and fructose Does not transport galactose, 2-deoxy-d-glucose and xylose.
Gene Name
SLC2A7
Uniprot ID
Q6PXP3
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 7
Molecular Weight
55726.915 Da
References
  1. Mueckler M, Thorens B: The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38. doi: 10.1016/j.mam.2012.07.001. [PubMed:23506862]
Details8. Solute carrier family 2, facilitated glucose transporter member 8
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Glucose transmembrane transporter activity
Specific Function
Insulin-regulated facilitative glucose transporter. Binds cytochalasin B in a glucose-inhibitable manner. Seems to be a dual-specific sugar transporter as it is inhibitable by fructose (By similari...
Gene Name
SLC2A8
Uniprot ID
Q9NY64
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 8
Molecular Weight
50818.54 Da
References
  1. Mueckler M, Thorens B: The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38. doi: 10.1016/j.mam.2012.07.001. [PubMed:23506862]
Details9. Solute carrier family 2, facilitated glucose transporter member 9
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Sugar:proton symporter activity
Specific Function
Transport urate and fructose. May have a role in the urate reabsorption by proximal tubules. Also transports glucose at low rate.
Gene Name
SLC2A9
Uniprot ID
Q9NRM0
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 9
Molecular Weight
58701.205 Da
References
  1. Mueckler M, Thorens B: The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38. doi: 10.1016/j.mam.2012.07.001. [PubMed:23506862]
Details10. Solute carrier family 2, facilitated glucose transporter member 10
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Sugar:proton symporter activity
Specific Function
Facilitative glucose transporter.
Gene Name
SLC2A10
Uniprot ID
O95528
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 10
Molecular Weight
56910.77 Da
References
  1. Mueckler M, Thorens B: The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38. doi: 10.1016/j.mam.2012.07.001. [PubMed:23506862]
Details11. Solute carrier family 2, facilitated glucose transporter member 11
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Substrate-specific transmembrane transporter activity
Specific Function
Facilitative glucose transporter.
Gene Name
SLC2A11
Uniprot ID
Q9BYW1
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 11
Molecular Weight
53702.055 Da
References
  1. Mueckler M, Thorens B: The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38. doi: 10.1016/j.mam.2012.07.001. [PubMed:23506862]
Details12. Solute carrier family 2, facilitated glucose transporter member 12
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Substrate-specific transmembrane transporter activity
Specific Function
Facilitative glucose transporter.
Gene Name
SLC2A12
Uniprot ID
Q8TD20
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 12
Molecular Weight
66965.7 Da
References
  1. Mueckler M, Thorens B: The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38. doi: 10.1016/j.mam.2012.07.001. [PubMed:23506862]
Details13. Sodium/glucose cotransporter 1
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Glucose:sodium symporter activity
Specific Function
Actively transports glucose into cells by Na(+) cotransport with a Na(+) to glucose coupling ratio of 2:1. Efficient substrate transport in mammalian kidney is provided by the concerted action of a...
Gene Name
SLC5A1
Uniprot ID
P13866
Uniprot Name
Sodium/glucose cotransporter 1
Molecular Weight
73497.275 Da
References
  1. Roder PV, Geillinger KE, Zietek TS, Thorens B, Koepsell H, Daniel H: The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One. 2014 Feb 26;9(2):e89977. doi: 10.1371/journal.pone.0089977. eCollection 2014. [PubMed:24587162]
Details14. Sodium/glucose cotransporter 2
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Low-affinity glucose:sodium symporter activity
Specific Function
Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capac...
Gene Name
SLC5A2
Uniprot ID
P31639
Uniprot Name
Sodium/glucose cotransporter 2
Molecular Weight
72895.995 Da
References
  1. Roder PV, Geillinger KE, Zietek TS, Thorens B, Koepsell H, Daniel H: The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One. 2014 Feb 26;9(2):e89977. doi: 10.1371/journal.pone.0089977. eCollection 2014. [PubMed:24587162]

Drug created on June 13, 2005 13:24 / Updated on January 07, 2021 03:10